These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 1666324)
1. Indications for the use of cytomegalovirus-seronegative blood products. Preiksaitis JK Transfus Med Rev; 1991 Jan; 5(1):1-17. PubMed ID: 1666324 [No Abstract] [Full Text] [Related]
2. [Leukocyte depletion and infection by cytomegalovirus]. Mazeron MC Transfus Clin Biol; 2000 Jun; 7 Suppl 1():31s-35s. PubMed ID: 10919221 [TBL] [Abstract][Full Text] [Related]
6. [Is serologic screening necessary in the donor bloods for cytomegalovirus seronegative blood transfusion to risky patients?]. Mutlu B; Günlemez A; Türker G; Gökalp AS; Willke A Mikrobiyol Bul; 2008 Apr; 42(2):337-41. PubMed ID: 18697432 [TBL] [Abstract][Full Text] [Related]
7. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469 [TBL] [Abstract][Full Text] [Related]
8. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland. Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012 [TBL] [Abstract][Full Text] [Related]
9. The incidence and consequences of cytomegalovirus transmission via blood transfusion to low birth weight, premature infants in north east Scotland. Galea G; Urbaniak SJ Vox Sang; 1992; 62(4):200-7. PubMed ID: 1322610 [TBL] [Abstract][Full Text] [Related]
10. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346 [TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. Bowden RA; Sayers M; Flournoy N; Newton B; Banaji M; Thomas ED; Meyers JD N Engl J Med; 1986 Apr; 314(16):1006-10. PubMed ID: 3007984 [TBL] [Abstract][Full Text] [Related]
17. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Landaw EM; Kanter M; Petz LD Blood; 1996 Jun; 87(11):4910. PubMed ID: 8639866 [No Abstract] [Full Text] [Related]
18. Why is cytomegalovirus the most frequent cause of congenital infection? Lazzarotto T; Lanari M Expert Rev Anti Infect Ther; 2011 Oct; 9(10):841-3. PubMed ID: 21973293 [No Abstract] [Full Text] [Related]
19. [Cytomegalovirus hyperimmune globulin and cytomegalovirus-tested blood products--a pilot study in bone marrow graft recipients]. Beelen DW; Neumann MC; Mahmoud HK; Henneberg K; Thraenhart O; Schaefer UW Immun Infekt; 1985 Sep; 13(5):229-32. PubMed ID: 2998980 [TBL] [Abstract][Full Text] [Related]